|
Gene: CEP170 |
Gene summary for CEP170 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CEP170 | Gene ID | 9859 |
Gene name | centrosomal protein 170 | |
Gene Alias | FAM68A | |
Cytomap | 1q43 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q5SW79 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9859 | CEP170 | LZE2T | Human | Esophagus | ESCC | 8.29e-04 | 6.43e-01 | 0.082 |
9859 | CEP170 | LZE4T | Human | Esophagus | ESCC | 2.65e-12 | 2.56e-01 | 0.0811 |
9859 | CEP170 | LZE7T | Human | Esophagus | ESCC | 1.69e-12 | 9.27e-01 | 0.0667 |
9859 | CEP170 | LZE8T | Human | Esophagus | ESCC | 3.94e-03 | 1.04e-01 | 0.067 |
9859 | CEP170 | LZE21D1 | Human | Esophagus | HGIN | 3.33e-03 | 2.11e-01 | 0.0632 |
9859 | CEP170 | LZE22T | Human | Esophagus | ESCC | 1.01e-05 | 4.14e-01 | 0.068 |
9859 | CEP170 | LZE24T | Human | Esophagus | ESCC | 7.19e-15 | 2.65e-01 | 0.0596 |
9859 | CEP170 | P2T-E | Human | Esophagus | ESCC | 1.06e-28 | 4.82e-01 | 0.1177 |
9859 | CEP170 | P4T-E | Human | Esophagus | ESCC | 1.39e-13 | 2.82e-01 | 0.1323 |
9859 | CEP170 | P5T-E | Human | Esophagus | ESCC | 3.97e-17 | 3.65e-01 | 0.1327 |
9859 | CEP170 | P8T-E | Human | Esophagus | ESCC | 1.18e-06 | 1.46e-01 | 0.0889 |
9859 | CEP170 | P9T-E | Human | Esophagus | ESCC | 9.19e-14 | 2.32e-01 | 0.1131 |
9859 | CEP170 | P10T-E | Human | Esophagus | ESCC | 2.65e-19 | 3.44e-01 | 0.116 |
9859 | CEP170 | P11T-E | Human | Esophagus | ESCC | 3.84e-10 | 4.86e-01 | 0.1426 |
9859 | CEP170 | P12T-E | Human | Esophagus | ESCC | 3.08e-25 | 5.10e-01 | 0.1122 |
9859 | CEP170 | P15T-E | Human | Esophagus | ESCC | 1.57e-16 | 3.87e-01 | 0.1149 |
9859 | CEP170 | P16T-E | Human | Esophagus | ESCC | 6.79e-34 | 6.78e-01 | 0.1153 |
9859 | CEP170 | P17T-E | Human | Esophagus | ESCC | 5.05e-04 | 2.92e-01 | 0.1278 |
9859 | CEP170 | P19T-E | Human | Esophagus | ESCC | 6.94e-09 | 6.69e-01 | 0.1662 |
9859 | CEP170 | P20T-E | Human | Esophagus | ESCC | 2.08e-11 | 3.00e-01 | 0.1124 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CEP170 | SNV | Missense_Mutation | c.4069N>T | p.Arg1357Cys | p.R1357C | Q5SW79 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CEP170 | SNV | Missense_Mutation | c.3356N>T | p.Ala1119Val | p.A1119V | Q5SW79 | protein_coding | tolerated(0.23) | probably_damaging(0.99) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CEP170 | SNV | Missense_Mutation | c.2983N>T | p.Arg995Cys | p.R995C | Q5SW79 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CEP170 | SNV | Missense_Mutation | novel | c.2373N>G | p.Asn791Lys | p.N791K | Q5SW79 | protein_coding | tolerated(0.92) | benign(0.007) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CEP170 | SNV | Missense_Mutation | c.1349N>T | p.Ser450Leu | p.S450L | Q5SW79 | protein_coding | deleterious(0.01) | benign(0.035) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CEP170 | SNV | Missense_Mutation | rs769238371 | c.3541G>A | p.Ala1181Thr | p.A1181T | Q5SW79 | protein_coding | tolerated(0.16) | benign(0.125) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CEP170 | SNV | Missense_Mutation | novel | c.3398C>A | p.Ser1133Tyr | p.S1133Y | Q5SW79 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CEP170 | SNV | Missense_Mutation | novel | c.1820C>A | p.Ser607Tyr | p.S607Y | Q5SW79 | protein_coding | deleterious(0.01) | benign(0.169) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CEP170 | SNV | Missense_Mutation | novel | c.2774G>C | p.Arg925Thr | p.R925T | Q5SW79 | protein_coding | tolerated(0.16) | possibly_damaging(0.663) | TCGA-AX-A2IO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
CEP170 | SNV | Missense_Mutation | novel | c.3227C>A | p.Ser1076Tyr | p.S1076Y | Q5SW79 | protein_coding | deleterious(0) | possibly_damaging(0.564) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |